Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

155

P595 Steroids in Post COVID-19 Interstitial Lung Disease/ P. Ntiamoah, Cleveland, OH P596 Effects of Amiodarone on COVID-19 Pneumonia Outcomes/ A.K. Rahman, Bethlehem, PA P597 De Novo Eosinophilic Granulomatous With Polyangiitis (EGPA) Following COVID-19 Infection or Vaccination/ G. Alrehaili, Rochester, MN P598 Mortality of SARS-CoV-2 Infection in Patients With Fibrotic Interstitial Lung Disease/ K. Donohoe, Cincinnati, OH P599 Acceptance and Adherence to Coronavirus Disease 2019 Vaccination Among Interstitial Lung Disease Patients/ R. Dinparastisaleh, Jacksonville, FL P600 Effect of COVID-19 Disease on Lung Functions in Idiopathic Pulmonary Fibrosis Patients/ M. Sterclova, Prague, Czech Republic P601 Multiorgan Involvement Is a Risk Factor for COVID-19 Infection in Sarcoidosis Patients/ A.V. Pulapaka, Baltimore, MD P602 In the Era of COVID-19: Outcomes in Rituximab Therapy in Interstitial Lung Disease/ R. Strykowski, Chicago, IL P603 SouthEastern SArcoidosis Registry (SESAR): Variation in Clinical Characteristics and Prescribing Patterns in Sarcoidosis Across Academic Medical Centers/ D.J. Dennis, Charleston, SC P604 Analysis of Cardiac MRI With T2 Mapping in Cardiac Sarcoidosis/ D.J. Dennis, Charleston, SC P605 Prevalence, Incidence, and Patients’ Characteristics of Cardiac Sarcoidosis in Patients With Biopsy-proven Pulmonary Sarcoidosis/ T. Sato, Sapporo, Japan P606 Role of Screening for Uveitis in Subjects With Sarcoidosis/ M.L. Wilsher, Auckland, New Zealand P607 Prevalence and Epidemiology of Pulmonary Hypertension Amongst Patients With Sarcoidosis/ J.R. Shah, Ahmedabad, India P608 Airborne Fungal Antigen Exposure Is Associated With Disease Severity and Lung Fibrosis in Patients With Sarcoidosis/ M. Shlossman, Iowa City, IA P609 Lofgren’s Syndrome: Prognostically as Good as We Think?/ B. Karakaya, Nieuwegein, Netherlands P610 Comparison Between Complete Versus Limited Granulomatous Inflammation in Thoracic Lymph Nodes on the Clinical Course of Sarcoidosis/ M. Kassirer, Beer Sheeva, Israel P611 Pulmonary Rehabilitation in Sarcoidosis: A Systematic Review and Meta-analysis/ J. Sellares Torres, Barcelona, Spain

CLINICAL THEMATIC POSTER SESSION

B39

ADVANCES IN LUNG TRANSPLANTATION

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area E, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P583 Technical Aspects of Bronchoscopic Balloon Dilatation in Patients With Bronchial Stenosis After Lung Transplantation/ M.S. Ki, Seoul, Korea, Republic of P584 Increased Airway Dehiscence in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients/ R. Koshy, Pittsburgh, PA P585 Evaluation of Indications, Contra-Indications and Willingness for Lung Transplant in Patients With Chronic Respiratory Illness at a Tertiary Care Centre in India/ A. Mohan, New Delhi, India P586 Post-transplant Native Lung and Allograft Volumes in Single Lung Recipients/ M. Zulty, Philadelphia, PA P587 High-altitude Does Not Modify the Outcomes After Lung Transplantation/ F.A. Varon, Bogota, Colombia P588 The Effect of Fluid Balance on Post-operative Outcomes in Lung Transplant Patients: A Retrospective Cohort Study/ T. Thompson, Maywood, IL P589 Transfusion Requirements During Lung Transplantation: A Single Center, Retrospective Cohort Analysis/ B. Gordon, New York, NY P590 Patient Engagement With a Bespoke Remote Monitoring Program For Follow-up Care Post-lung Transplantation/ R. Borton, Dublin, Ireland P591 Evolution of Allograft Function in Lung Transplant Recipients With and Without Aspiration/ J. Gagermeier, Maywood, IL

CLINICAL THEMATIC POSTER SESSION

B40

POTPOURRI IN ILD: SPANNING THE SPECTRUM FROM RARE TO COMMON LUNG DISEASES

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area F, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussionwith assigned facilitators.

ATS 2023 • Washington, DC